New Vaccines for Chronic Respiratory Patients

Chronic respiratory diseases (CRD) are responsible for more than four million deaths worldwide and have become especially prevalent in developed countries. Although the current therapies help manage daily symptoms and improve patients’ quality of life, there is a major need to prevent exacerbations...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Archivos de bronconeumología (English ed.) 2024-09, Vol.60 (9), p.565-575
Hauptverfasser: Mallah, Narmeen, Urbieta, Ana Dacosta, Rivero-Calle, Irene, Gonzalez-Barcala, Francisco-Javier, Bigoni, Tommaso, Papi, Alberto, Martinón-Torres, Federico
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 575
container_issue 9
container_start_page 565
container_title Archivos de bronconeumología (English ed.)
container_volume 60
creator Mallah, Narmeen
Urbieta, Ana Dacosta
Rivero-Calle, Irene
Gonzalez-Barcala, Francisco-Javier
Bigoni, Tommaso
Papi, Alberto
Martinón-Torres, Federico
description Chronic respiratory diseases (CRD) are responsible for more than four million deaths worldwide and have become especially prevalent in developed countries. Although the current therapies help manage daily symptoms and improve patients’ quality of life, there is a major need to prevent exacerbations triggered mainly by respiratory infections. Therefore, CRD patients are a prime target for vaccination against infectious agents. In the present manuscript we review the state of the art of available vaccines specifically indicated in patients with CRDs. In addition to pneumococcus, influenza, pertussis, and SARS-CoV-2 vaccines, recently added immunization options like vaccines and monoclonal antibodies against respiratory syncytial virus, are particularly interesting in CRD patients. As new products reach the market, health authorities must be agile in updating immunization recommendations and in the programming of the vaccination of vulnerable populations such as patients with CRDs. Organizational and educational strategies might prove useful to increase vaccine uptake by CRD patients.
doi_str_mv 10.1016/j.arbres.2024.05.026
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_3068749889</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S030028962400190X</els_id><sourcerecordid>3068749889</sourcerecordid><originalsourceid>FETCH-LOGICAL-c2726-681e2ccec7d154659623ec5edea8d606e463ff7bf4995cc58c09bf6026ac959b3</originalsourceid><addsrcrecordid>eNp9kMtOwzAQRS0EoqXwBwhlySZh7MSOvUFCFS8JAULA1nImE-GqTYqdgvr3pGphyWo2587VPYydcsg4cHUxy1yoAsVMgCgykBkItcfGXJYmFVyYfTaGHCAV2qgRO4pxBiBkXohDNsq1LpXheszSR_pO3h2ibykmTReS6UfoWo_JC8WlD67vwjp5dr2nto_H7KBx80gnuzthbzfXr9O79OHp9n569ZCiKIVKleYkEAnLmstCSaNETiipJqdrBYoKlTdNWTWFMRJRagRTNWoY4NBIU-UTdr79uwzd54pibxc-Is3nrqVuFW0OSpeF0doMaLFFMXQxBmrsMviFC2vLwW5E2ZndirIbURakHXqG2NmuYVUtqP4L_ZoZgMstQMPOL0_BRhwcINU-EPa27vz_DT-3b3p9</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3068749889</pqid></control><display><type>article</type><title>New Vaccines for Chronic Respiratory Patients</title><source>Elsevier ScienceDirect Journals Complete</source><creator>Mallah, Narmeen ; Urbieta, Ana Dacosta ; Rivero-Calle, Irene ; Gonzalez-Barcala, Francisco-Javier ; Bigoni, Tommaso ; Papi, Alberto ; Martinón-Torres, Federico</creator><creatorcontrib>Mallah, Narmeen ; Urbieta, Ana Dacosta ; Rivero-Calle, Irene ; Gonzalez-Barcala, Francisco-Javier ; Bigoni, Tommaso ; Papi, Alberto ; Martinón-Torres, Federico</creatorcontrib><description>Chronic respiratory diseases (CRD) are responsible for more than four million deaths worldwide and have become especially prevalent in developed countries. Although the current therapies help manage daily symptoms and improve patients’ quality of life, there is a major need to prevent exacerbations triggered mainly by respiratory infections. Therefore, CRD patients are a prime target for vaccination against infectious agents. In the present manuscript we review the state of the art of available vaccines specifically indicated in patients with CRDs. In addition to pneumococcus, influenza, pertussis, and SARS-CoV-2 vaccines, recently added immunization options like vaccines and monoclonal antibodies against respiratory syncytial virus, are particularly interesting in CRD patients. As new products reach the market, health authorities must be agile in updating immunization recommendations and in the programming of the vaccination of vulnerable populations such as patients with CRDs. Organizational and educational strategies might prove useful to increase vaccine uptake by CRD patients.</description><identifier>ISSN: 0300-2896</identifier><identifier>ISSN: 1579-2129</identifier><identifier>EISSN: 1579-2129</identifier><identifier>DOI: 10.1016/j.arbres.2024.05.026</identifier><identifier>PMID: 38876918</identifier><language>eng</language><publisher>Spain: Elsevier España, S.L.U</publisher><subject>Chronic respiratory diseases ; Influenza ; Monoclonal antibody ; Pertussis ; Pneumococcal disease vaccine ; Respiratory syncytial virus ; SARS-CoV-2 ; Vaccine</subject><ispartof>Archivos de bronconeumología (English ed.), 2024-09, Vol.60 (9), p.565-575</ispartof><rights>2024 The Authors</rights><rights>Copyright © 2024 The Authors. Published by Elsevier España, S.L.U. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c2726-681e2ccec7d154659623ec5edea8d606e463ff7bf4995cc58c09bf6026ac959b3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.arbres.2024.05.026$$EHTML$$P50$$Gelsevier$$Hfree_for_read</linktohtml><link.rule.ids>314,777,781,3537,27905,27906,45976</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38876918$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Mallah, Narmeen</creatorcontrib><creatorcontrib>Urbieta, Ana Dacosta</creatorcontrib><creatorcontrib>Rivero-Calle, Irene</creatorcontrib><creatorcontrib>Gonzalez-Barcala, Francisco-Javier</creatorcontrib><creatorcontrib>Bigoni, Tommaso</creatorcontrib><creatorcontrib>Papi, Alberto</creatorcontrib><creatorcontrib>Martinón-Torres, Federico</creatorcontrib><title>New Vaccines for Chronic Respiratory Patients</title><title>Archivos de bronconeumología (English ed.)</title><addtitle>Arch Bronconeumol</addtitle><description>Chronic respiratory diseases (CRD) are responsible for more than four million deaths worldwide and have become especially prevalent in developed countries. Although the current therapies help manage daily symptoms and improve patients’ quality of life, there is a major need to prevent exacerbations triggered mainly by respiratory infections. Therefore, CRD patients are a prime target for vaccination against infectious agents. In the present manuscript we review the state of the art of available vaccines specifically indicated in patients with CRDs. In addition to pneumococcus, influenza, pertussis, and SARS-CoV-2 vaccines, recently added immunization options like vaccines and monoclonal antibodies against respiratory syncytial virus, are particularly interesting in CRD patients. As new products reach the market, health authorities must be agile in updating immunization recommendations and in the programming of the vaccination of vulnerable populations such as patients with CRDs. Organizational and educational strategies might prove useful to increase vaccine uptake by CRD patients.</description><subject>Chronic respiratory diseases</subject><subject>Influenza</subject><subject>Monoclonal antibody</subject><subject>Pertussis</subject><subject>Pneumococcal disease vaccine</subject><subject>Respiratory syncytial virus</subject><subject>SARS-CoV-2</subject><subject>Vaccine</subject><issn>0300-2896</issn><issn>1579-2129</issn><issn>1579-2129</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><recordid>eNp9kMtOwzAQRS0EoqXwBwhlySZh7MSOvUFCFS8JAULA1nImE-GqTYqdgvr3pGphyWo2587VPYydcsg4cHUxy1yoAsVMgCgykBkItcfGXJYmFVyYfTaGHCAV2qgRO4pxBiBkXohDNsq1LpXheszSR_pO3h2ibykmTReS6UfoWo_JC8WlD67vwjp5dr2nto_H7KBx80gnuzthbzfXr9O79OHp9n569ZCiKIVKleYkEAnLmstCSaNETiipJqdrBYoKlTdNWTWFMRJRagRTNWoY4NBIU-UTdr79uwzd54pibxc-Is3nrqVuFW0OSpeF0doMaLFFMXQxBmrsMviFC2vLwW5E2ZndirIbURakHXqG2NmuYVUtqP4L_ZoZgMstQMPOL0_BRhwcINU-EPa27vz_DT-3b3p9</recordid><startdate>20240901</startdate><enddate>20240901</enddate><creator>Mallah, Narmeen</creator><creator>Urbieta, Ana Dacosta</creator><creator>Rivero-Calle, Irene</creator><creator>Gonzalez-Barcala, Francisco-Javier</creator><creator>Bigoni, Tommaso</creator><creator>Papi, Alberto</creator><creator>Martinón-Torres, Federico</creator><general>Elsevier España, S.L.U</general><scope>6I.</scope><scope>AAFTH</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20240901</creationdate><title>New Vaccines for Chronic Respiratory Patients</title><author>Mallah, Narmeen ; Urbieta, Ana Dacosta ; Rivero-Calle, Irene ; Gonzalez-Barcala, Francisco-Javier ; Bigoni, Tommaso ; Papi, Alberto ; Martinón-Torres, Federico</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c2726-681e2ccec7d154659623ec5edea8d606e463ff7bf4995cc58c09bf6026ac959b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Chronic respiratory diseases</topic><topic>Influenza</topic><topic>Monoclonal antibody</topic><topic>Pertussis</topic><topic>Pneumococcal disease vaccine</topic><topic>Respiratory syncytial virus</topic><topic>SARS-CoV-2</topic><topic>Vaccine</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Mallah, Narmeen</creatorcontrib><creatorcontrib>Urbieta, Ana Dacosta</creatorcontrib><creatorcontrib>Rivero-Calle, Irene</creatorcontrib><creatorcontrib>Gonzalez-Barcala, Francisco-Javier</creatorcontrib><creatorcontrib>Bigoni, Tommaso</creatorcontrib><creatorcontrib>Papi, Alberto</creatorcontrib><creatorcontrib>Martinón-Torres, Federico</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Archivos de bronconeumología (English ed.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Mallah, Narmeen</au><au>Urbieta, Ana Dacosta</au><au>Rivero-Calle, Irene</au><au>Gonzalez-Barcala, Francisco-Javier</au><au>Bigoni, Tommaso</au><au>Papi, Alberto</au><au>Martinón-Torres, Federico</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>New Vaccines for Chronic Respiratory Patients</atitle><jtitle>Archivos de bronconeumología (English ed.)</jtitle><addtitle>Arch Bronconeumol</addtitle><date>2024-09-01</date><risdate>2024</risdate><volume>60</volume><issue>9</issue><spage>565</spage><epage>575</epage><pages>565-575</pages><issn>0300-2896</issn><issn>1579-2129</issn><eissn>1579-2129</eissn><abstract>Chronic respiratory diseases (CRD) are responsible for more than four million deaths worldwide and have become especially prevalent in developed countries. Although the current therapies help manage daily symptoms and improve patients’ quality of life, there is a major need to prevent exacerbations triggered mainly by respiratory infections. Therefore, CRD patients are a prime target for vaccination against infectious agents. In the present manuscript we review the state of the art of available vaccines specifically indicated in patients with CRDs. In addition to pneumococcus, influenza, pertussis, and SARS-CoV-2 vaccines, recently added immunization options like vaccines and monoclonal antibodies against respiratory syncytial virus, are particularly interesting in CRD patients. As new products reach the market, health authorities must be agile in updating immunization recommendations and in the programming of the vaccination of vulnerable populations such as patients with CRDs. Organizational and educational strategies might prove useful to increase vaccine uptake by CRD patients.</abstract><cop>Spain</cop><pub>Elsevier España, S.L.U</pub><pmid>38876918</pmid><doi>10.1016/j.arbres.2024.05.026</doi><tpages>11</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0300-2896
ispartof Archivos de bronconeumología (English ed.), 2024-09, Vol.60 (9), p.565-575
issn 0300-2896
1579-2129
1579-2129
language eng
recordid cdi_proquest_miscellaneous_3068749889
source Elsevier ScienceDirect Journals Complete
subjects Chronic respiratory diseases
Influenza
Monoclonal antibody
Pertussis
Pneumococcal disease vaccine
Respiratory syncytial virus
SARS-CoV-2
Vaccine
title New Vaccines for Chronic Respiratory Patients
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-17T14%3A49%3A25IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=New%20Vaccines%20for%20Chronic%20Respiratory%20Patients&rft.jtitle=Archivos%20de%20bronconeumologi%CC%81a%20(English%20ed.)&rft.au=Mallah,%20Narmeen&rft.date=2024-09-01&rft.volume=60&rft.issue=9&rft.spage=565&rft.epage=575&rft.pages=565-575&rft.issn=0300-2896&rft.eissn=1579-2129&rft_id=info:doi/10.1016/j.arbres.2024.05.026&rft_dat=%3Cproquest_cross%3E3068749889%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3068749889&rft_id=info:pmid/38876918&rft_els_id=S030028962400190X&rfr_iscdi=true